Bladder cancer trial probes immune response before surgery
NCT ID NCT03978624
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study looks at how two drugs, pembrolizumab and entinostat, change the immune system in people with muscle-invasive bladder cancer who cannot have standard chemotherapy. About 20 participants receive the drugs before their scheduled bladder removal surgery. The goal is to measure immune-related gene activity, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.